Search

Background: Calcium hydroxyapatite (CaHA)‐carboxymethylcellulose (CMC)+ has unique properties that make it optimal for lifting, contouring, and defining the jawline. This long‐term follow‐up of a randomized, multicenter, rater‐blinded trial reports efficacy and safety of CaHA‐CMC(+) through 48 and up to 60 weeks post‐treatment. Methods: Eligible patients were randomized (2:1) to the treatment or the control/delayed treatment group to receive CaHA‐CMC(+) injections in both jawlines. While touch‐ups were permitted 4 weeks post‐treatment for both groups, only the treatment group was eligible for optional retreatment after 48 weeks. The primary outcome was ≥1‐point improvement on both jawlines on the Merz Jawline Assessment Scale (MJAS); secondary endpoints included the Subject Global Aesthetic Improvement Scale (SGAIS) among others. Post hoc analysis included pooling up to 48‐week data from the combined treatment and control/delayed groups and 60‐week data for the treatment group. Results: Overall, 175 received treatment. MJAS responder rates were 77.9%, 78.7%, and 62.9% at 12, 24, and 48 weeks post‐treatment, respectively. Responder rate on the MJAS at 60 weeks was 74.6% for those who received retreatment and 43.5% for those patients who received only the initial and touchup treatments. SGAIS scores demonstrated 93.4%, 85.6%, and 68.5% of patients rated themselves very much improved after 12, 24, and 48 weeks, respectively. Adverse events consisted of procedure or CaHA‐CMC(+)‐related events that were mostly resolved and overwhelmingly mild. Conclusions: CaHA‐CMC(+) produced clinically meaningful and long‐lasting improvements in jawline contour and was well tolerated in patients through 60 weeks. Trial Registration: ClinicalTrials.gov Identifier: NCT03583359. [ABSTRACT FROM AUTHOR]

As dermal fillers have evolved, volume restoration and contour enhancement have become the objective of advanced injectors. The value of injections of dermal fillers into the midface is well documented in the literature. However, the midface, particularly the infraorbital hollow, is the facial area most prone to adverse events from filler treatment. Malar edema is a particularly significant and long-lasting untoward event that is frequently reported. This article reviews the anatomic basis for malar edema, relates it to filler injection technique, and presents the author's preferred method of injection to help ensure avoidance of this adverse event. [ABSTRACT FROM AUTHOR]